WASHINGTON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- On Sept. 10, more than 50 citizen lobbyists representing a consortium of 15 national nonprofits and organizations gathered on Capitol Hill for the first ...

With more than 40,000 patients treated so far, Smile Hair Clinic continues to be a pioneer in the field of advanced hair transplantation with natural-looking results and cutting-edge technology.

Villepinte, le 15 septembre 2025, 17h45 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, annonce une révision à la baisse de ses ...

Villepinte, 15 September 2025, 5.45 p.m.: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing a downward revision to its financial ...

ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine Kinases (c-Abl kinases), announces that the final results ...

Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of September 2025, which is payable ...

INmune Bio Inc. (NASDAQ: INMB) (“INmune” or “the Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to ...

Phase 2 TOIVA trial successfully met recruitment target, enrolling 16 subjects at leading vascular anomaly centers; top-line data expected in mid-December 2025 Venous malformations are the most common ...

Oral semaglutide (Rybelsus ®) is now the first and only oral GLP-1 RA approved for type 2 diabetes, with proven cardiovascular benefits 1; This approval is based on results from ...

(Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Linda M.

Her appointment follows Atavistik Bio’s recent initiation of a Phase 1 clinical trial evaluating ATV-1601, an allosteric selective inhibitor for AKT1 E17K-driven solid tumors She will also play a ...

(p=0.0919). Clinical improvement in King’s Sarcoidosis Questionnaire (KSQ)-Lung score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0479). Greater proportion of ...